Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Sponsor
- Mayo Clinic
- Enrollment
- 1000
- Locations
- 4
- Primary Endpoint
- Collection of biospecimens from patients who developed cardiac toxicity (CRCT) or who are at high risk for developing CRCT
- Status
- Recruiting
- Last Updated
- 4 months ago
Overview
Brief Summary
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Detailed Description
PRIMARY OBJECTIVE: I. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT identified prior to the onset of therapy. OUTLINE: This is an observational study. Patients undergo blood sample collection and have their medical records reviewed on study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years of age or older
- •Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
- •One of the following:
- •Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
- •Completed chemotherapy with no cardiotoxicity at least two years post treatment
- •Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
- •An understanding of the protocol and its requirements, risks, and discomforts
- •The ability and willingness to sign an informed consent
Exclusion Criteria
- •\- Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Outcomes
Primary Outcomes
Collection of biospecimens from patients who developed cardiac toxicity (CRCT) or who are at high risk for developing CRCT
Time Frame: Baseline
Assessed by the number of participants who participate and consent to have their specimen (blood draw) retained for future research.